LAS VEGAS, May 11, 2015 (GLOBE NEWSWIRE) -- Growblox Sciences Inc. (OTCQB:GBLX) ("Growblox" or the "Company"), a biopharmaceutical research and development company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, announced today the launch of its new corporate website.
"We have navigated many obstacles in the process of refining our vision and gathering a complete understanding of the medicinal cannabis landscape. We believe that our evolution has enabled a compelling message to emerge very clearly, which we are pleased to present on our new corporate site; Growblox is here to cultivate an industry , not just a plant," said CEO Craig Ellins.
The corporate site http://www.Growblox.com provides extensive content regarding the Company's position in the market and is intended to highlight three (3) operating divisions of the Company: GB Sciences, GB Solutions and GB Products.
- GB Sciences : Handles all regulatory, compliance, clinical trials, product claim validation and new drug discovery. Led by Growblox Sciences' Chief Science Officer, Dr. Andrea Small-Howard, this division is expected to collaborate with academic and institutional partners, such as the University of Puerto Rico and various clinical research organizations, in order to create a novel cannabinoid therapy pipeline.
- GB Solutions : Focuses on supply chain and logistics and will be overseen by Puerto Rican business leader Cesar Cordero-Kruger, as head of our majority owned subsidiary Growblox Sciences Puerto Rico, LLC. Under his leadership the GB Solutions division will be responsible for all engineering, industrial design and systems validation including the commercialization of company's propriety cultivation system known as the GrowBLOX™ Technology Suite .
- GB Products : Expected to be formally launched by the end of Q3 2015. Lead by Growblox Sciences' Co-founder Lucas Marin, this division will be taking over product design, marketing and distribution of consumer ready cannabinoid therapies and specialized products.
The website also features the Company's focus on scientific validation for the medical cannabis industry, supply chain solutions designed to set a path for national distribution and the strong brand identities that will lead the future of cannabinoid therapies. This is the first step of the new communication strategy that the biotechnology company will deploy to target potential partners and investors in the fast growing medical cannabis space.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (OTCQB:GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The Company is leading pioneering technology and industry processes, with a "big" data-driven clinical research and development loop ability to bring relief to patients in communities across the country. Through our GBSPR subsidiary, we are developing and distributing our GrowBLOX TM suite of cultivation and growing chambers. To learn more about Growblox Sciences, Inc., go to www.gbsciences.com .
Forward-Looking Statements : This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov . All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note : Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as presently constituted.
Growblox Sciences, Inc. Cathryn Kennedy 702-576-5704
